[go: up one dir, main page]

CN103509002B - Purification decolorization method of fasudil hydrochloride - Google Patents

Purification decolorization method of fasudil hydrochloride Download PDF

Info

Publication number
CN103509002B
CN103509002B CN201210203958.1A CN201210203958A CN103509002B CN 103509002 B CN103509002 B CN 103509002B CN 201210203958 A CN201210203958 A CN 201210203958A CN 103509002 B CN103509002 B CN 103509002B
Authority
CN
China
Prior art keywords
fasudil
fasudil hydrochloride
dichloromethane solution
hydrochloride
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210203958.1A
Other languages
Chinese (zh)
Other versions
CN103509002A (en
Inventor
许光
关记存
姚浩
张蒙生
陈晨
鲁艺
乔德水
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Wan Bang Biochemical Medicine Co ltd
Jiangsu Wanbang Biopharmaceutical Group Co ltd
China Pharmaceutical University
Xuzhou Wanbang Jinqiao Pharmaceutical Co Ltd
Original Assignee
Shanghai Fosun Pharmaceutical Group Co Ltd
Xuzhou Wanbang Jinqiao Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fosun Pharmaceutical Group Co Ltd, Xuzhou Wanbang Jinqiao Pharmaceutical Co Ltd filed Critical Shanghai Fosun Pharmaceutical Group Co Ltd
Priority to CN201210203958.1A priority Critical patent/CN103509002B/en
Publication of CN103509002A publication Critical patent/CN103509002A/en
Application granted granted Critical
Publication of CN103509002B publication Critical patent/CN103509002B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a crude drug processing method, particularly relates to a purification decolorization method of a crude drug, and more particularly relates to a purification decolorization method of fasudil hydrochloride. Aiming at the problem that in the prior art a fasudil hydrochloride product is purified and decolored by organic solvent recrystallization, the new purification decolorization method of the fasudil hydrochloride is provided, through direct pH adjusting of a fasudil dichloromethane solution and matched filtering operation, the fasudil hydrochloride product is separated from pigments and water soluble impurities, a new idea that a crude drug hydrochloride can be crystallized in an aqueous solution is developed, so that the problem of organic compound recrystallion in an organic solution in the prior art is solved.

Description

一种盐酸法舒地尔的纯化脱色方法A kind of purification and decolorization method of fasudil hydrochloride

技术领域 technical field

本发明涉及一种原料药的处理方法,特别是涉及一种原料药的纯化脱色方法,更为具体的说是涉及一种盐酸法舒地尔的纯化脱色方法。 The present invention relates to a kind of treatment method of crude drug, particularly relate to a kind of purification decolorization method of crude drug, more specifically relate to a kind of purification decolorization method of fasudil hydrochloride.

背景技术 Background technique

盐酸法舒地尔是一种蛋白激酶抑制剂即细胞内钙离子拮抗剂,其药理作用为通过阻断血管收缩过程的最终阶段,即球蛋白轻链磷酸化的这一过程,来扩张血管,从而抑制血管痉挛。其药学制品在临床上适用于改善和预防蛛网膜下腔出血后的脑痉挛及引起的脑缺血症状。 Fasudil hydrochloride is a protein kinase inhibitor or intracellular calcium ion antagonist. Its pharmacological action is to dilate blood vessels by blocking the final stage of the vasoconstriction process, that is, the phosphorylation of globulin light chains. thereby inhibiting vasospasm. Its pharmaceutical products are clinically suitable for improving and preventing cerebral spasm after subarachnoid hemorrhage and the symptoms of cerebral ischemia caused by it.

盐酸法舒地尔的临床常用剂型为注射剂,因此对其颜色及纯度的要求都极为严格,如何对盐酸法舒地尔进行脱色纯化显得尤为重要。 The commonly used clinical dosage form of Fasudil hydrochloride is injection, so the requirements for its color and purity are extremely strict. How to decolorize and purify Fasudil hydrochloride is particularly important.

现有工艺中纯化的方法基本可以分为两步,第一步采用有机溶剂重结晶法如US5942505等对产品进行脱色纯化,第二步利用化合物的游离碱对有机相及水相双相剔除作用如EP1726306及专利CN101723934A等,或者是通过硅胶层析柱如US5942505、EP187371及专利CN101812051A等对产品进行脱色纯化。不可避免的,首先都要采用有机溶剂重结晶法对产品进行第一步的纯化脱色过程及有机碱性原料药的双相剔除,但问题是如此做的结果往往不尽人意,而不断的重复这两个过程不但让操作更为繁复,损失更大外,结果也是差强人意。 The purification method in the existing process can basically be divided into two steps. The first step adopts the organic solvent recrystallization method such as US5942505 to decolorize and purify the product, and the second step uses the free base of the compound to remove the organic phase and the aqueous phase. Such as EP1726306 and patent CN101723934A, etc., or decolorize and purify the product through silica gel chromatography column such as US5942505, EP187371 and patent CN101812051A. Inevitably, the first step of purifying and decolorizing the product by using the organic solvent recrystallization method and the two-phase elimination of the organic basic raw material drug, but the problem is that the result of doing so is often unsatisfactory, and it is repeated continuously These two processes not only make the operation more complicated and the loss greater, but the result is not satisfactory.

发明内容 Contents of the invention

本发明针对目前盐酸法舒地尔利用有机溶剂重结晶对产品脱色纯化中存在的问题提供了一种新的盐酸法舒地尔的纯化脱色方法,包括以下步骤: The present invention provides a new purification and decolorization method of fasudil hydrochloride for the problems existing in the current fasudil hydrochloride using organic solvent recrystallization to decolorize and purify the product, comprising the following steps:

(1)制得法舒地尔的二氯甲烷溶液; (1) Prepare the dichloromethane solution of Fasudil;

(2)调节步骤(1)中法舒地尔二氯甲烷溶液的pH值至4.5~5.5; (2) adjusting the pH value of the fasudil dichloromethane solution in step (1) to 4.5-5.5;

(3)降低体系温度至0℃以下,搅拌,保温半个小时; (3) Lower the temperature of the system to below 0°C, stir, and keep warm for half an hour;

(4)将步骤(3)中的得到的混合物过滤,收集滤饼,得盐酸法舒地尔脱色纯化品。 (4) Filter the mixture obtained in step (3), collect the filter cake, and obtain the decolorized purified product of Fasudil hydrochloride.

作为一种改进,所述步骤(2)中采用稀盐酸调节法舒地尔二氯甲烷溶液的pH值。 As an improvement, dilute hydrochloric acid is used in the step (2) to adjust the pH value of the fasudil dichloromethane solution.

作为另一改进,所述步骤(1)中法舒地尔二氯甲烷溶液的制备方法为:将5-异喹啉磺酰氯的二氯甲烷溶液滴加至高哌嗪的二氯甲烷溶液。 As another improvement, the preparation method of the fasudil dichloromethane solution in the step (1) is: adding the dichloromethane solution of 5-isoquinolinesulfonyl chloride dropwise to the dichloromethane solution of homopiperazine.

本发明通过直接对法舒地尔二氯甲烷溶液的pH调节,配合过滤操作,将色素及水溶性杂质与盐酸法舒地尔产品实现分离,开辟了原料药的盐酸盐在水溶液里析晶的新思路,使得以往有机化合物在有机溶液中重结晶解决不了的问题得到了解决。 The present invention directly adjusts the pH of the fasudil dichloromethane solution and cooperates with the filtration operation to separate the pigment and water-soluble impurities from the fasudil hydrochloride product, and opens up the crystallization of the hydrochloride of the raw material drug in the aqueous solution The new idea has solved the problems that could not be solved by the recrystallization of organic compounds in organic solution in the past.

具体实施方式 Detailed ways

实施例1 Example 1

盐酸法舒地尔的纯化脱色方法,包括以下步骤: The purification and decolorization method of fasudil hydrochloride comprises the following steps:

(1)制得法舒地尔的二氯甲烷溶液; (1) Prepare the dichloromethane solution of Fasudil;

(2)调节步骤(1)中法舒地尔二氯甲烷溶液的pH值至4.5~5.5; (2) adjusting the pH value of the fasudil dichloromethane solution in step (1) to 4.5-5.5;

(3)降低体系温度至0℃以下,搅拌,保温半个小时; (3) Lower the temperature of the system to below 0°C, stir, and keep warm for half an hour;

(4)将步骤(3)中的得到的混合物过滤,收集滤饼,得盐酸法舒地尔脱色品。 (4) Filter the mixture obtained in step (3), collect the filter cake, and obtain the decolorized product of Fasudil hydrochloride.

实施例2 Example 2

盐酸法舒地尔的纯化脱色方法,包括以下步骤: The purification and decolorization method of fasudil hydrochloride comprises the following steps:

(1)将5-异喹啉磺酰氯的二氯甲烷溶液滴加至高哌嗪的二氯甲烷溶液,制得法舒地尔的二氯甲烷溶液; (1) Add the dichloromethane solution of 5-isoquinolinesulfonyl chloride dropwise to the dichloromethane solution of homopiperazine to prepare the dichloromethane solution of fasudil;

(2)调节步骤(1)中法舒地尔二氯甲烷溶液的pH值至4.5~5.5; (2) adjusting the pH value of the fasudil dichloromethane solution in step (1) to 4.5-5.5;

(3)降低体系温度至0℃以下,搅拌,保温半个小时; (3) Lower the temperature of the system to below 0°C, stir, and keep warm for half an hour;

(4)将步骤(3)中的得到的混合物过滤,收集滤饼,得盐酸法舒地尔脱色品。 (4) Filter the mixture obtained in step (3), collect the filter cake, and obtain the decolorized product of Fasudil hydrochloride.

实施例3 Example 3

盐酸法舒地尔的纯化脱色方法,包括以下步骤: The purification and decolorization method of fasudil hydrochloride comprises the following steps:

(1)制得法舒地尔的二氯甲烷溶液; (1) Prepare the dichloromethane solution of Fasudil;

(2)逐步滴加稀盐酸至溶液体系中,调节步骤(1)中法舒地尔二氯甲烷溶液的pH值至4.5~5.5; (2) Gradually drop dilute hydrochloric acid into the solution system, and adjust the pH value of the fasudil dichloromethane solution in step (1) to 4.5-5.5;

(3)降低体系温度至0℃以下,搅拌,保温半个小时; (3) Lower the temperature of the system to below 0°C, stir, and keep warm for half an hour;

(4)将步骤(3)中的得到的混合物过滤,收集滤饼,得盐酸法舒地尔脱色品。 (4) Filter the mixture obtained in step (3), collect the filter cake, and obtain the decolorized product of Fasudil hydrochloride.

实施例4 Example 4

第一步:向反应釜中,加入高哌嗪二氯甲烷混合液,冷冻降温至0℃,滴加5-异喹啉磺酰氯的二氯甲烷液,控制反应液温度在5℃以下,滴加完毕后,反应液呈黄绿色。 Step 1: Add homopiperazine dichloromethane mixture to the reaction kettle, freeze and cool down to 0°C, add 5-isoquinolinesulfonyl chloride in dichloromethane dropwise, control the temperature of the reaction solution below 5°C, drop After the addition, the reaction solution was yellow-green.

滴加4mol/L盐酸水溶液至反应体系中,调节pH至5。 Add 4 mol/L hydrochloric acid aqueous solution dropwise to the reaction system to adjust the pH to 5.

降温,当体系温度约15℃时开始析出白色固体,继续降温至0℃以下,保温半个小时,过滤,滤饼为类白色固体,滤液为黄绿色,其中含有色素及溶于酸性水溶液的杂质。 Cool down, when the temperature of the system is about 15°C, a white solid begins to precipitate, continue to cool down to below 0°C, keep warm for half an hour, filter, the filter cake is off-white solid, and the filtrate is yellow-green, which contains pigments and impurities soluble in acidic aqueous solution .

第二步:按照EP1726306及专利CN101723934A 所公开的方法进一步对脱色后的盐酸法舒地尔进行纯化。具体过程如下:将类白色固体滤饼溶解于水中,加入二氯甲烷,洗涤,静置分层,弃去二氯甲烷有机相(其中含有可溶于二氯甲烷的部分杂质),取水相待用。调节水溶液pH至10以上,再次加入二氯甲烷,萃取,静置分层,弃取水溶液(其中含有可溶于碱性水溶液的部分杂质),取二氯甲烷有机相,向得到的二氯甲烷溶液中加入成盐试剂,过滤,得盐酸法舒地尔粗品。粗品用约90%乙醇水溶液重结晶,得盐酸法舒地尔纯品,HPLC含量:99.97%,单个最大杂质0.03%,颜色低于黄色0.5号。 Second step: according to the method disclosed in EP1726306 and patent CN101723934A, the decolorized Fasudil hydrochloride is further purified. The specific process is as follows: Dissolve the off-white solid filter cake in water, add dichloromethane, wash, let it stand for stratification, discard the organic phase of dichloromethane (which contains some impurities soluble in dichloromethane), and take the water phase to wait use. Adjust the pH of the aqueous solution to above 10, add dichloromethane again, extract, let stand to separate layers, discard the aqueous solution (which contains some impurities soluble in alkaline aqueous solution), take the organic phase of dichloromethane, and pour the obtained dichloromethane A salt-forming reagent was added to the solution, and filtered to obtain the crude product of Fasudil hydrochloride. The crude product was recrystallized with about 90% ethanol aqueous solution to obtain pure Fasudil hydrochloride, HPLC content: 99.97%, single largest impurity 0.03%, color lower than yellow 0.5.

与文献中方法所得到的盐酸法舒地尔相比(CN101812051A柱层析方法得到99.96%),不仅获取产品的成本较低,颜色完全合格、含量更高,操作简单,适合生产。 Compared with Fasudil hydrochloride obtained by the method in the literature (99.96% obtained by CN101812051A column chromatography method), not only the cost of obtaining the product is lower, the color is completely qualified, the content is higher, the operation is simple, and it is suitable for production.

本发明方案所公开的技术手段不仅限于上述技术手段所公开的技术手段,还包括由以上技术特征任意组合所组成的技术方案。 The technical means disclosed in the solution of the present invention are not limited to the technical means disclosed in the above technical means, but also include technical solutions composed of any combination of the above technical features.

以上所述是本发明的具体实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也视为本发明的保护范围。 The above are specific implementations of the present invention. It should be pointed out that for those of ordinary skill in the art, without departing from the principle of the present invention, some improvements and modifications can also be made, and these improvements and modifications are also considered Be the protection scope of the present invention.

Claims (3)

1. a Purification decolorization method for Fasudil Hydrochloride, is characterized in that comprising the following steps:
(1) dichloromethane solution of obtained fasudil;
(2) pH value to 4.5 ~ 5.5 of the middle fasudil dichloromethane solution of regulating step (1);
(3) reduce below system temperature to 0 DEG C, stir, insulation half hour;
(4) mixture obtained in step (3) is filtered, collect filter cake, obtain Fasudil Hydrochloride decolouring purifying product.
2., according to the Purification decolorization method of the Fasudil Hydrochloride described in claim 1, it is characterized in that in described step (2), adopting dilute hydrochloric acid to regulate the pH value of fasudil dichloromethane solution.
3., according to the Purification decolorization method of the Fasudil Hydrochloride described in claim 1, it is characterized in that the preparation method of the dichloromethane solution of fasudil in described step (1) is: the dichloromethane solution dichloromethane solution of 5-isoquinoline sulfonyl chloride being dropped to homopiperazine.
CN201210203958.1A 2012-06-20 2012-06-20 Purification decolorization method of fasudil hydrochloride Active CN103509002B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210203958.1A CN103509002B (en) 2012-06-20 2012-06-20 Purification decolorization method of fasudil hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210203958.1A CN103509002B (en) 2012-06-20 2012-06-20 Purification decolorization method of fasudil hydrochloride

Publications (2)

Publication Number Publication Date
CN103509002A CN103509002A (en) 2014-01-15
CN103509002B true CN103509002B (en) 2015-05-13

Family

ID=49892482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210203958.1A Active CN103509002B (en) 2012-06-20 2012-06-20 Purification decolorization method of fasudil hydrochloride

Country Status (1)

Country Link
CN (1) CN103509002B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945381B (en) * 2015-06-24 2019-05-03 山东罗欣药业集团股份有限公司 A kind of fasudil hydrochloride compound, preparation method and its pharmaceutical composition
CN109970712A (en) * 2017-12-27 2019-07-05 徐州万邦金桥制药有限公司 A kind of refining methd of Fasudic hydrochloride
CN109705096B (en) * 2019-03-07 2023-06-09 山东新华制药股份有限公司 Refining method of fasudil hydrochloride

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102002036A (en) * 2009-08-31 2011-04-06 秦引林 Method for refining fasudil
CN102020635A (en) * 2009-09-10 2011-04-20 河北凯盛医药科技有限公司 Preparation method of hydrochloride Fasudil hemihydrate
CN102120739A (en) * 2010-01-07 2011-07-13 成都欣捷高新技术开发有限公司 Preparation method of fasudil hydrochloride
CN102241669A (en) * 2010-05-13 2011-11-16 吉林省博大伟业制药有限公司 Preparation method of fasudil hydrochloride

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102002036A (en) * 2009-08-31 2011-04-06 秦引林 Method for refining fasudil
CN102020635A (en) * 2009-09-10 2011-04-20 河北凯盛医药科技有限公司 Preparation method of hydrochloride Fasudil hemihydrate
CN102120739A (en) * 2010-01-07 2011-07-13 成都欣捷高新技术开发有限公司 Preparation method of fasudil hydrochloride
CN102241669A (en) * 2010-05-13 2011-11-16 吉林省博大伟业制药有限公司 Preparation method of fasudil hydrochloride

Also Published As

Publication number Publication date
CN103509002A (en) 2014-01-15

Similar Documents

Publication Publication Date Title
JP5479105B2 (en) Novel ubiquitin-binding small molecule
CN111163766A (en) AHR inhibitors and uses thereof
CN104844585A (en) Preparation method of brexpiprazole
CN106256824B (en) Preparation method of high-purity delafloxacin meglumine salt
CN103509002B (en) Purification decolorization method of fasudil hydrochloride
CN104402838B (en) The process for purification of valsartan
AU2021349249A1 (en) Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals
EP2743258B1 (en) Method for purifying levo-oxiracetam
WO2024040768A1 (en) 5-pyridine-1h-indazole compound, pharmaceutical composition, and use
CN109988167A (en) A kind of preparation method of Tadalafei
WO2005080392A1 (en) Pyrazoloquinolone derivative and use thereof
CN103044323B (en) A kind of purification process of SASP
CN104277053B (en) A kind of preparation method of Cefodizime and its intermediate cefodizime acid
CN105481856A (en) Preparation method of palipefidone
CN102924436A (en) Refining method of fasudil hydrochloride
CN102260253B (en) Benzo[5,6]cycloheptyl[1,2-b]pyridine derivatives and preparation method thereof, and pharmaceutical composition and application thereof in anaphylactic disease resistance
TW201412745A (en) Crystal of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-YL]-2- oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
CN104119307A (en) Preparation method for (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-B]furan-8-yl)ethylamine
CN103819398B (en) The synthetic method of the chloro-3-nitropyridine of 4-amino-2-
CN109810115B (en) Isoflavone compound and preparation method and application thereof
CN108084158A (en) The preparation method of R-lansoprazole
CA3108158C (en) 5-methyl-4-fluoro-thiazol-2-yl compounds
JP6085900B2 (en) Olanzapine production method
CN109970712A (en) A kind of refining methd of Fasudic hydrochloride
CN104558103A (en) Preparation method of argatroban intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160516

Address after: 221004, Jiangsu, Xuzhou Jinshan Development Zone, comprehensive area, the south side of the Cave Hill

Patentee after: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Patentee after: CHINA PHARMACEUTICAL University

Patentee after: JIANGSU WANBANG BIOPHARMACEUTICALS Co.,Ltd.

Address before: 221004 Jiangsu city in Xuzhou Province Economic Development Zone Xuzhou peach Mountain Road No. 7

Patentee before: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Patentee before: CHINA PHARMACEUTICAL University

CP01 Change in the name or title of a patent holder

Address after: 221004, Jiangsu, Xuzhou Jinshan Development Zone, comprehensive area, the south side of the Cave Hill

Co-patentee after: CHINA PHARMACEUTICAL University

Patentee after: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Co-patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP CO.,LTD.

Address before: 221004, Jiangsu, Xuzhou Jinshan Development Zone, comprehensive area, the south side of the Cave Hill

Co-patentee before: CHINA PHARMACEUTICAL University

Patentee before: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Co-patentee before: Jiangsu Wan Bang Biochemical Medicine Co.,Ltd.

Address after: 221004, Jiangsu, Xuzhou Jinshan Development Zone, comprehensive area, the south side of the Cave Hill

Co-patentee after: CHINA PHARMACEUTICAL University

Patentee after: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Co-patentee after: Jiangsu Wan Bang Biochemical Medicine Co.,Ltd.

Address before: 221004, Jiangsu, Xuzhou Jinshan Development Zone, comprehensive area, the south side of the Cave Hill

Co-patentee before: CHINA PHARMACEUTICAL University

Patentee before: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Co-patentee before: JIANGSU WANBANG BIOPHARMACEUTICALS Co.,Ltd.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20180214

Address after: 221004 Jiangsu city in Xuzhou Province Economic Development Zone Xuzhou peach Mountain Road No. 7

Co-patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP CO.,LTD.

Patentee after: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Address before: 221004, Jiangsu, Xuzhou Jinshan Development Zone, comprehensive area, the south side of the Cave Hill

Co-patentee before: CHINA PHARMACEUTICAL University

Patentee before: Xuzhou Wanbang Jinqiao Pharmaceutical Co.,Ltd.

Co-patentee before: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP CO.,LTD.

TR01 Transfer of patent right